2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - 353-355
Technology and Procedures, Assays, Omics Technologies, Bioinformatics, Computational Biology, Treatment Considerations, Supportive Care, Biological Therapies, Transplantation, Biological Processes, Genomics, Clinical Practice (Health Services and Quality), Diseases, Immunology, GVHD, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Registries, Study Population, Human, Adult, Elderly, Pediatric
PAPER

571 Outcomes of second allogeneic hematopoietic stem cell transplantation with post-transplant cyclophosphamide across donor types

Yosra M. Aljawai, MD MS, Denai Milton2, Chiara Adina Hummel, MD3, Portia Smallbone, MBBS (Hons), FRACP, FRCPA4, Warren Fingrut, MD, MPH5, Partow Kebriaei, MD6, William Matsui, MD7, Uday Popat, MD, MBA8, Betul Oran, MD9, Muzaffar Qazilbash, MD10, Qaiser Bashir, MD11, Chitra Hosing, MD12, Richard Champlin13, Elizabeth Shpall, MD14
1 MD Anderson Cancer Center, Houston, Texas, United States
2 MD Anderson Cancer Center, Houston, Texas, United States
3 MD Anderson Cancer Center, Houston, Texas, United States
4 MD Anderson Cancer Center, Houston, Texas, United States
5 MD Anderson Cancer Center, Houston, Texas, United States, MD Anderson Cancer Center, Houston, Texas, United States
6 MD Anderson Cancer Center, Houston, Texas, United States
7 MD Anderson Cancer Center, Houston, Texas, United States
8 MD Anderson Cancer Center, Houston, Texas, United States
9 MD Anderson Cancer Center, Houston, Texas, United States
10 MD Anderson Cancer Center, Houston, Texas, United States
11 MD Anderson Cancer Center, Houston, Texas, United States
12 MD Anderson Cancer Center, Houston, Texas, United States
13 MD Anderson Cancer Center, Houston, Texas, United States
14 MD Anderson Cancer Center, Houston, Texas, United States

Background:

Relapse after first allogeneic hematopoietic stem cell transplantation (HCT1) remains the leading cause of treatment failure. A second transplant (HCT2) is an established curative option for post-transplant relapse. Recent adoption of post-transplant cyclophosphamide (PTCy)- based graft-vs-host-disease (GVHD) prophylaxis has expanding access to HCT2 with alternative donors. We evaluated outcomes of PTCy-based HCT2 across donor types.

 

Methods:

We retrospectively analyzed consecutive adults with hematologic malignancies who underwent PTCy-based HCT2 after relapse following HCT1 with any GVHD prophylaxis at MD Anderson Cancer Center between 2002-2025. Survival outcomes were estimated using the Kaplan-Meier method and associations with clinically relevant covariates assessed by Cox proportional hazards regression models. Relapse, non-relapse mortality (NRM), and graft-versus-host disease (GVHD) were estimated using proportional subdistribution hazards regression modeling accounting for competing risks. Primary endpoint was progression-free survival (PFS); secondary endpoints were overall survival (OS), relapse, NRM, and GVHD.

Results:

A total of 179 patients underwent HCT2 (acute myeloid leukemia: 65%, acute lymphoblastic leukemia 16%, myeloproliferative neoplasms/myelodysplastic syndromes 15%, and 4% lymphoma, CML, and CLL). Median recipient age: 48 years (range: 19-77). 51% had HCT-comorbidity index (HCT-CI) score ≥ 3, 82% received reduced intensity conditioning, 76% received peripheral blood, and 45% received PTCy for HCT1. Donors were matched unrelated (MUD, 43%), haploidentical (haplo, 36%), matched sibling (MSD, 15%) and mismatched unrelated (MMUD, 7%). Median donor age: 33 years (range: 13-70); MSD were oldest: median 57 years (range: 17-70), MMUD (39.5, range: 23-47), haplo (33, range: 13-61), and MUD (29.5, range: 18-56). Median time from HCT1 to relapse:13 months (range: 1-245). Median follow-up of survivors was 25.7 months (range: 2.5-166.5). Patients with CR prior to HCT2 (63%). Of the 71% who had evaluable samples for measurable residual disease (MRD), 52% were MRD-positive by flowcytometry (FC) at a sensitivity of 10-3.

One-year PFS was 40%, OS 54%, relapse 31%, NRM 29%. Grade II-IV and III-IV aGVHD at 6 months were 34%, and 8%, respectively. One-year cGVHD was 5%. Relapse was the most common reason for death across all donors (56%) and was highest among recipients of MSD (71%), MUD (64%), haplo (47%), and MMUD (38%).

In multivariable analysis, donor age was the only donor-related factor associated with PFS (hazard ratio [95% CI] 1.02 [1.00-1.03], P=.030) associated with OS and NRM. Compared to MSD, all donor types associated with increased NRM in MUD (1.80 [0.56-5.74], P=.32) and MMUD (3.43 [0.74-15.98], P=.12), and haplo: (3.32 [1.08-10.28], P=.037). This risk was offset by lower relapse in MUD (0.92 [0.48-1.76], P=.81) and MMUD (0.63 [0.23-1.73], P=.37) and haplo (0.48 [0.24-0.96], P=.037). Accordingly, donor type showed comparable survival to MSD. Only 11% (19/179) received the same donor for both transplants, which was associated with reduced NRM (0.22 [0.06-0.85], P=0.028). However, this finding should be interpreted cautiously given the limited sample size.

Non-donor related predictors of outcomes included FC-MRD positivity (PFS: 1.91 [1.15-3.16], P= 0.012); (relapse: 2.02 [1.15-3.55], P=0.015). Notably, morphological CR did not emerge as a significant predictor of outcomes. Comorbidity burden (HCT-CI ≥3) was associated with inferior OS (1.69 [1.15-2.49], P=0.008) and NRM (2.22 [1.25-3.96], P=0.007). Use of PTCy in both transplants was not associated with worse outcomes. No predictors were associated with increased risk of acute or chronic GVHD.

Conclusion:

In this uniform PTCy- based HCT2, alternative donors achieved comparable survival to MSD, expanding the donor pool for patients relapsing after HCT1. Haplo donors were associated with lower relapse, suggesting an advantage over MSD for select patients with lower risk of NRM. Donor age emerged as an independent predictor and should inform donor selection when available. FC-MRD was a strong predictor of relapse and survival and warrants integration into pre-HCT risk stratification. In this high-relapse group of patients undergoing a second transplant, with 40% alive and relapse-free at one-year without excess GVHD, these encouraging results support broader investigation of alternative donors and MRD-stratified approaches in larger cohorts.

Yosra M. Aljawai, MD MS: No relevant conflicts of interest to declare.